



May 13, 2026

**To,
Listing Department,
BSE Limited
Phiroze Jeejeebhoy Towers,
Dalal Street,
Mumbai – 400 001
Ref: BSE Scrip Code: 544497**

**To,
The National Stock Exchange of India Ltd.
The Listing Department
Exchange Plaza,
Bandra – Kurla Complex,
Mumbai – 400051,
NSE Scrip Code: AHCL**

Sub: Submission of Monitoring Agency Report for the Quarter ended on March 31, 2026.

Dear Sir/Madam,

Pursuant to Regulation 30 and 32 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, and Regulation 41(2) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations"), please find enclosed herewith the Monitoring Agency Report issued by CRISIL RATINGS LIMITED for the Quarter ended on March 31, 2026.

You are requested to take the above information on your record

Thanking You.

Yours Faithfully,
FOR, ANLON HEALTHCARE LIMITED

**PUNITKUMAR RASADIA
MANAGING DIRECTOR
DIN: 06696258**

ANLON HEALTHCARE LIMITED

CIN No.: U24230GJ2013PLC077543

REGISTERED OFFICE: 101/102, Silver Coin Complex, Opp. Crystal Mall, Kalawad Road, Rajkot-360005, Gujarat (INDIA)

PHONE NO.: +91-7069690081/82 | Email: info@anlonhealthcare.com | www.anlon.in

Monitoring Agency Report
for
Anlon Healthcare Limited
for the quarter ended
March 31, 2026

CRL/MAR/ANLHLP/2025-26/1751

May 12, 2026

To

Anlon Healthcare Limited

101/102, Silvercoin Complex, Opp. Crystal Mall,
Kalawad Road, Rajkot - 360 005, Gujarat, India

Dear Sir,


**Monitoring Agency Report for the quarter ended March 31, 2026 - in relation to the Initial Public Offer
("IPO") of Anlon Healthcare Limited ("the Company")**

Pursuant to Regulation 41(2) of SEBI (Issue of Capital and Disclosure Requirements) Regulations, 2018 ("SEBI ICDR Regulations") and Monitoring Agency Agreement dated August 12, 2025, enclosed herewith the Monitoring Agency Report, issued by Crisil Ratings Limited, Monitoring Agency, as per Schedule XI of the SEBI ICDR Regulations towards utilization of proceeds of IPO for the quarter ended March 31, 2026.

Request you to kindly take the same on records.

Thanking you,

For and on behalf of Crisil Ratings Limited



Shounak Chakravarty
Director, Ratings (LCG)

Report of the Monitoring Agency (MA)

Name of the issuer: Anlon Healthcare Limited

For quarter ended: March 31, 2026

Name of the Monitoring Agency: Crisil Ratings Limited

(a) Deviation from the objects: Yes, *Refer Note 1*

Note 1: Deviation is observed in the utilization of funds against the objects stated in the Prospectus however, utilization is in line with change of objects as per the Shareholder's approval dated January 07, 2026. Specifically, the Company has expanded the scope of the object viz. "Funding capital expenditure requirements for expansion of Manufacturing Facility ("Proposed Expansion")" and added "proposed expansion through inorganic growth and further upgradations"

(b) Range of Deviation: Not applicable

Declaration:

We declare that this report provides an objective view of the utilization of the issue proceeds in relation to the objects of the issue based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The MA does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives. This Report is not intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever. Nothing mentioned in this report is intended to or should be construed as creating a fiduciary relationship between the MA and any issuer or between the agency and any user of this report. The MA and its affiliates also do not act as an expert as defined under Section 2(38) of the Companies Act, 2013.

The MA or its affiliates may have credit rating or other commercial transactions with the entity to which the report pertains and may receive separate compensation for its ratings and certain credit-related analyses. We confirm that we do not perceive any conflict of interest in such relationship/interest while monitoring and reporting the utilization of the issue proceeds by the issuer.

We have submitted the report herewith in line with the format prescribed by SEBI, capturing our comments, where applicable. There are certain sections of the report under the title "Comments of the Board of Directors", that shall be captured by the Issuer's Management / Audit Committee of the Board of Directors subsequent to the MA submitting their report to the issuer and before dissemination of the report through stock exchanges. These sections have not been reviewed by the MA, and the MA takes no responsibility for such comments of the issuer's Management/Board.

Signature: 

Name and designation of the Authorized Signatory: Shounak Chakravarty

Designation of Authorized person/Signing Authority: Director, Ratings (LCG)

1) Issuer Details:

Name of the issuer:	Anlon Healthcare Limited
Names of the promoter:	a. Punit Kumar R Rasadia b. Meet Atul Kumar Vachhani
Industry/sector to which it belongs:	Pharmaceuticals

2) Issue Details

Issue Period:	Tuesday, August 26, 2025 to Friday, August 29, 2025
Type of issue (public/rights):	Initial Public Offer (IPO)
Type of specified securities:	Equity Shares
IPO Grading, if any:	NA
Issue size:	Fresh Issue - Rs 12,103.00 lakh*

*Note:

Particulars	Amount (Rs lakh)
Gross proceeds of the Fresh Issue	12,103.00#
Less: Issue Expenses	1,513.05
Net Proceeds	10,589.95

#Crisil Ratings shall be monitoring the gross proceeds.

3) Details of the arrangement made to ensure the monitoring of issue proceeds:

Particulars	Reply	Source of information/certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all utilization is as per the disclosures in the Offer Document?	Yes	Management undertaking, Statutory Auditor certificate [^] , Prospectus, Bank Statements, Postal Ballot Notice	Refer Note 1 & Note 2	No Comments
Whether shareholder approval has been obtained in case of material deviations from expenditures disclosed in the Offer Document?	Yes	Management undertaking, Statutory Auditor certificate [^] , Shareholder's resolution	Refer Note 1 & 3	No Comments
Whether the means of finance for the disclosed objects of the issue has changed?	No	Management undertaking, Statutory Auditor certificate [^]	No Comments	No Comments
Is there any major deviation observed over the earlier monitoring agency reports?	No	Management undertaking, Statutory Auditor certificate [^]	No Comments	No Comments

Particulars	Reply	Source of information/certifications considered by Monitoring Agency for preparation of report	Comments of the Monitoring Agency	Comments of the Board of Directors
Whether all Government/statutory approvals related to the object(s) have been obtained?	NA	Management undertaking, Statutory Auditor certificate [^]	No Comments	No Comments
Whether all arrangements pertaining to technical assistance/collaboration are in operation?	NA		No Comments	No Comments
Are there any favorable events improving the viability of these object(s)?	No		No Comments	No Comments
Are there any unfavorable events affecting the viability of the object(s)?	No		No Comments	No Comments
Is there any other relevant information that may materially affect the decision making of the investors?	No		No Comments	No Comments

NA represents Not Applicable

[^] Based on Certificate dated May 07, 2026, issued by M/s R V D & Co, Chartered Accountants (Firm Registration Number: 143936W), Statutory Auditor of the Company.

Note 2: Certificate dated May 07, 2026, issued by M/s R V D & Co, Chartered Accountants (Firm Registration Number: 143936W), Statutory Auditor of the Company mentions "During the period under review, the Company has utilized IPO proceeds for the purpose of acquisition of the following two entities:

Name of Entity	Amount (Rs in Lakhs)	Other Details
Bizotic Life Science Private Limited	379.69	Acquisition of 25,50,000 equity shares at a price of Rs 14.89 per share, aggregating to Rs 379.69 lakhs
Apiqo Organics Private Limited (formerly M/s Apple Lifesciences)	540.06	Acquisition of 55,33,500 equity shares at a price of Rs 9.76 per share, aggregating to Rs 540.06 lakhs

Further, the company has obtained the necessary approvals from the shareholders in respect of the aforesaid acquisitions, in compliance with the applicable provisions of the Companies Act, 2013 and the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015"

Note 3: Management undertaking and certificate dated May 07, 2026, issued by M/s R V D & Co, Chartered Accountants (Firm Registration Number: 143936W), Statutory Auditor of the Company mentions "The Company obtained approval of the shareholders for variation in one of the objects disclosed in the offer documents for proposed expansion through inorganic growth and further upgradation, via postal ballot concluded on January 07, 2026"

4) Details of object(s) to be monitored:

i. Cost of the object(s):

Sr. No	Item Head	Source of information / certification considered by MA for preparation of report	Original cost (as per the Offer Document) (Rs in lakh)	Revised Cost (Rs in lakh)	Comment of the Monitoring Agency	Comments of the Board of Directors		
						Reason of Cost revision	Proposed financing option	Particulars of firm arrangements made
1	Funding capital expenditure requirements for Expansion of manufacturing facility and Inorganic growth and further upgradation	Management undertaking, Statutory Auditor certificate [^] , Prospectus	3,071.95	3,071.95	No revision	No Comments	No Comments	No Comments
2	Full or part repayment and/or prepayment of certain outstanding secured borrowings secured borrowing (term loan) availed by our Company		500.00	500.00	No revision	No Comments	No Comments	No Comments
3	Funding the working capital requirements of our Company		4,315.00	4,315.00	No revision	No Comments	No Comments	No Comments
4	General corporate purposes		2,703.00	2,787.39	Refer Note 4	No Comments	No Comments	No Comments
	Subtotal		10,589.95	10,674.34	-	-	-	-
5	Issue related expenses		1,513.05	1,428.66	Refer Note 4	No Comments	No Comments	No Comments
	Total	12,103.00	12,103.00	-	-	-	-	

[^] Based on Certificate dated May 07, 2026, issued by M/s R V D & Co, Chartered Accountants (Firm Registration Number: 143936W), Statutory Auditor of the Company.

Note 4: The Board of Directors vide resolution dated May 08, 2026, has revised the cost of objects on account that the actual issue expenses were Rs 84.39 lakhs lower than the estimates and accordingly has been reallocated to General Corporate Purposes.

#The amount to be utilised for general corporate purposes does not exceed 25% of the Gross Proceeds (Rs 3025.75 Lakhs)

ii. Progress in the object(s):

Sr. No.	Item Head#	Source of information/certifications considered by Monitoring Agency for preparation of report	Amount as proposed in the Offer Document (Rs in lakh)	Amount utilized (Rs in lakh) (Refer note 1)			Total unutilized amount (Rs in lakh)	Comments of the Monitoring Agency	Comments of the Board of Directors		
				As at beginning of the quarter	During the quarter	At the end of the quarter			Reasons for idle funds	Proposed course of action	
1	Funding capital expenditure requirements for Expansion of manufacturing facility and Inorganic growth and further Upgradation	Management undertaking, Statutory Auditor certificate [^] , Prospectus, Bank Statements	3,071.95	1,114.99	1,956.96	3,071.95	0.00	Refer Note 1, 5 & 6	No Comments	No Comments	
2	Full or part repayment and/or prepayment of certain outstanding secured borrowings secured borrowing (term loan) availed by the Company		500.00	500.00	0.00	500.00	0.00	No Comments	No Comments	No Comments	
3	Funding the working capital requirements of the Company		4,315.00	4,315.00	0.00	4315.00	0.00	No Comments	No Comments	No Comments	
4	General corporate purposes		2,787.39	2,232.19	542.00	2,774.19	13.20	Refer Note 4 & 5	No Comments	No Comments	
Subtotal			10,589.95	8,162.18	2,498.96	10,661.14	13.20	-	-	-	
5	Issue related expenses		1,428.66	1,416.86	11.80	1,428.66	0.00	Refer Note 4 & 5	No Comments	No Comments	
Total			12,103.00	9,579.04	2,510.76	12,089.80	13.20	-	-	-	

[^]Based on Certificate dated May 07, 2026, issued by M/s R V D & Co, Chartered Accountants (Firm Registration Number: 143936W), Statutory Auditor of the Company.

Note 5: During the quarter ended March 31, 2026, fixed deposits of Rs 1160.69 Lakhs held by the Company were redeemed and these proceeds were directly credited to the Company's current accounts. The Company has also transferred Rs 278.00 lakhs from the Monitoring account of the Company to its current accounts for utilization towards the objects of the issue. In total, during the reported quarter, the Company has utilized Rs 2,510.76 lakhs from current account, out of the credited proceeds, for utilization towards objects of the issue.

Note 6: The Company's vendor arrangements have undergone modifications compared to the disclosure in the prospectus dated August 30, 2025. Notably, the prospectus provides for such flexibility, as it states that "The quotations received from vendors in relation to the above-mentioned objects of the Issue are valid as on the date of this Prospectus. However, we have not entered into any definitive agreements with these vendors and there can be no assurance that the same vendor(s) would be engaged to eventually supply of any machinery and equipment, or we will get the machinery or civil and structured cost at the same costs." As a result, the modification of vendor arrangements is consistent with the disclosure outlined in the prospectus.

#Brief description of objects:

Object of the Issue	Description of objects as per the offer document filed by the issuer
Funding capital expenditure requirements for Proposed Expansion and inorganic growth and further upgradation	The company has taken land adjacent to its existing manufacturing facilities. The company intends to expand its manufacturing operations, pursuant to a board resolution dated April 14, 2025, and increase production capacity by establishing a new manufacturing plant on its owned freehold industrial land. (Refer Note 1)
Full or part repayment and/or prepayment of certain outstanding secured borrowings secured borrowing (term loan) availed by the Company	The Company has entered into financing arrangements to avail terms loans and working capital loans. The company propose to utilise an estimated amount of Rs 500.00 lakh from the Net Proceeds towards re-payment or pre-payment of borrowings, availed by the Company in full or in part. The repayment / prepayment, will help to reduce its outstanding indebtedness, assist it in maintaining a favourable debt-equity ratio and enable utilisation of some additional amount from its internal accruals for further investment in business growth and expansion.
Funding the working capital requirements of the Company	The Company is a chemical manufacturing company engaged in manufacturing of; (i) high purity advance pharmaceutical intermediates which are serves as raw material in the manufacturing of Active Pharmaceutical Ingredients (APIs); (ii) Active Pharmaceutical Ingredients which serves as a raw material for pharmaceutical formulations in preparation of various type of Finished Dosage Formula ("FDF") such as tablet, capsules, Ointment, Syrup etc, ingredients in nutraceuticals formulations, personal care products and animal health products. Currently the Company meets its working capital requirements in the ordinary course of its business from capital, internal accruals, unsecured loans, working capital loans from the Banks etc.
General corporate purposes	The Company intends to utilize Net proceeds towards general corporate purposes, and such amount shall not exceed 25% of the Gross Proceeds. The general corporate purposes for which the Company intends to utilize Net Proceeds include, subject to the above mentioned limit, as may be approved by our management, including but not restricted to, the following: a) Strategic initiatives; b) Brand building and strengthening of marketing activities; c) Ongoing general corporate exigencies; d) Any other purposes as approved by the Board and subject to compliance with the necessary regulatory provisions.

iii. Deployment of unutilised proceeds as at quarter ended March 31, 2026:

Based on management undertaking and Certificate dated May 07, 2026, issued by M/s R V D & Co, Chartered Accountants (Firm Registration Number: 143936W), Statutory Auditor of the Company.

S.No.	Type of instrument and name of the entity invested in	Amount invested (Rs. in lakh)	Maturity date	Earning (Rs. in lakh)	Return on Investment	Market value as at the end of reported quarter (Rs. in lakh)
1	Balance in Public Issue Account	13.20	-	-	-	13.20
	Total	13.20	-	-	-	13.20

iv. Delay in implementation of the object(s)^:

Object(s)	Completion Date		Delay (no. of days/ months)	Comments of the Board of Directors	
	As per the Offer Document	Actual		Reason of delay	Proposed course of action
Not applicable					

^Based on management undertaking and Certificate dated May 07, 2026, issued by M/s R V D & Co, Chartered Accountants (Firm Registration Number: 143936W), Statutory Auditor of the Company.

5) Details of utilization of proceeds stated as General Corporate Purpose amount in the offer document: Refer Note 7 & 8

Based on management undertaking and Certificate dated May 07, 2026, issued by M/s R V D & Co, Chartered Accountants (Firm Registration Number: 143936W), Statutory Auditor of the Company.

S. No.	Item heads	Amount (Rs in lakh)	Remarks
1	Meeting expenses incurred in ordinary business	520.00	Towards working capital requirements
	Total	520.00	-

Note 7: Based on management undertaking and Certificate dated May 07, 2026, issued by M/s R V D & Co, Chartered Accountants (Firm Registration Number: 143936W), Statutory Auditor of the Company, no payments were made to any directors, Key Managerial Personnel & Group Companies (excluding salaries paid as part of the regular course of business) from the proceeds of fresh issue.

Note 8: The Board of Directors of the Company vide resolution dated May 08, 2026, has ratified and approved the utilization of proceeds for payments under GCP for the mentioned sub-category.

Disclaimers:

- a) *This Report is prepared by Crisil Ratings Limited (hereinafter referred to as "Monitoring Agency" / "MA" / "CRL"). The MA has taken utmost care to ensure accuracy and objectivity while developing this Report based on the information provided by the Issuer and information obtained from sources believed by it to be accurate and reliable. The views and opinions expressed herein do not constitute the opinion of MA to deal in any security of the Issuer in any manner whatsoever.*
- b) *This Report has to be seen in its entirety; the selective review of portions of the Report may lead to inaccurate assessments. For the purpose of this Report, MA has relied upon the information provided by the management /officials/ consultants of the Issuer and third-party sources like Statutory Auditor'ss (or from peer reviewed CA firms) appointed by the Issuer believed by it to be accurate and reliable.*
- c) *Nothing contained in this Report is capable or intended to create any legally binding obligations on the MA which accepts no responsibility, whatsoever, for loss or damage from the use of the said information. The MA is also not responsible for any errors in transmission and specifically states that it, or its directors, employees do not have any financial liabilities whatsoever to the users of this Report.*
- d) *The MA and its affiliates do not act as a fiduciary. The MA and its affiliates also do not act as an expert to the extent defined under Section 2(38) of the Companies Act, 2013. While the MA has obtained information from sources it believes to be reliable, it does not perform an audit and undertakes no independent verification of any information/ certifications/ statements it receives from auditors (or from peer reviewed CA firms), lawyers, chartered engineers or other experts, and relies on in its reports.*
- e) *The MA or its affiliates may have other commercial transactions with the entity to which the report pertains. As an example, the MA may rate the issuer or any debt instruments / facilities issued or proposed to be issued by the issuer that is subject matter of this report. The MA may receive separate compensation for its ratings and certain credit-related analyses, normally from issuers or underwriters of the instruments, facilities, securities or from obligors.*
- f) *The MA report is intended for the jurisdiction of India only. This report does not constitute an offer of services. Without limiting the generality of the foregoing, nothing in the report is to be construed as CRL providing or intending to provide any services in jurisdictions outside India, where it does not have the necessary licenses and/or registration to carry out its business activities referred to above.*
- g) *Access or use of this report does not create a client relationship between CRL and the user.*
- h) *CRL is not aware that any user intends to rely on the report or of the manner in which a user intends to use the report. In preparing this report, MA has not taken into consideration the objectives or particular needs of any particular user.*
- i) *It is made abundantly clear that the report is not intended to and does not constitute an investment advice. The report is not an offer to sell or an offer to purchase or subscribe for any investment in any securities, instruments, facilities or solicitation of any kind to enter into any deal or transaction with the entity to which the report pertains. The report should not be a basis for any investment decision within the meaning of any law or regulation (including the laws and regulations applicable in the US).*
- j) *The report comprises professional opinion of CRL as of the date they are expressed, based on the information received from the issuer and other sources considered reliable by CRL. Any opinions expressed here are in good faith, are subject to change without notice, and are only current as of the stated date of their issue. The report does not constitute statements of fact or recommendations to purchase, hold or sell any securities/instruments or to make any investment decisions.*
- k) *Neither CRL nor its affiliates, third-party providers, as well as their directors, officers, shareholders, employees or agents guarantee the accuracy, completeness or adequacy of the report, and shall not have any liability for any errors, omissions or interruptions therein, regardless of the cause, or for the results obtained from the use of any part of the report. CRL and each aforesaid party disclaims any and all express or implied warranties, including but not limited to any warranties of merchantability, suitability or fitness for a particular purpose or use or use. In no event shall CRL or any aforesaid party be liable to any user for any direct, indirect, incidental, exemplary, compensatory, punitive, special or consequential damages, costs, expenses, legal fees or losses (including, without limitation, lost income or lost profits and opportunity costs) in connection with any use of any part of the report even if advised of the possibility of such damages.*

- l) CRL has established policies and procedures to maintain the confidentiality of certain non-public information received in connection with the preparation of this report. CRL has in place a code of conduct and policies for managing conflict of interest.*
- m) Unless required under any applicable law, this report should not be reproduced or redistributed to any other person or in any form without prior written consent from CRL.*
- n) By accepting a copy of this Report, the recipient accepts the terms of this Disclaimer, which forms an integral part of this Report.*